Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lyra Therapeutics, Inc. LYRA
$2.60
-$0.19 (-7.14%)
На 18:02, 12 мая 2023
+476.92%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
87244075.00000000
-
week52high
6.99
-
week52low
1.86
-
Revenue
1363000
-
P/E TTM
-2
-
Beta
-0.41508700
-
EPS
-2.01000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 24 мая 2022 г. | |
| Jefferies | Buy | 26 мая 2020 г. | |
| B of A Securities | Buy | 26 мая 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Richard Robert E. | A | 45000 | 45000 | 31 янв 2023 г. |
| Richard Robert E. | A | 30000 | 30000 | 31 янв 2023 г. |
| Waksal Harlan | A | 200000 | 200000 | 31 янв 2023 г. |
| Noyes Corinne | A | 55000 | 55000 | 31 янв 2023 г. |
| Noyes Corinne | A | 36667 | 36667 | 31 янв 2023 г. |
| Nieman Richard | A | 55537 | 55537 | 31 янв 2023 г. |
| Palasis Maria | A | 250000 | 250000 | 31 янв 2023 г. |
| Cavalier Jason | A | 140000 | 140000 | 31 янв 2023 г. |
| Nieman Richard | A | 230000 | 230000 | 11 июл 2022 г. |
| snyderman nancy lynn MD | A | 7250 | 7250 | 16 июн 2022 г. |
Новостная лента
Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting
PRNewsWire
29 авг 2022 г. в 07:00
WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the company will present additional Phase 2 results from the LANTERN study for LYR‑210, the company's lead product candidate for chronic rhinosinusitis, at the 68th Annual Meeting of the American Rhinologic Society (ARS), taking place September 9-10, 2022 in Philadelphia.
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
09 авг 2022 г. в 09:47
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics to Present at Upcoming Investor Conferences
PRNewsWire
26 мая 2022 г. в 07:00
WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.
Lyra Therapeutics: Progress In The Clinic
Seeking Alpha
18 мая 2022 г. в 12:46
Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile.
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2022 г. в 09:47
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?